Amgen Stock Price, News & Analysis (NASDAQ:AMGN)

$189.28 1.69 (0.90 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$189.28
Today's Range$187.60 - $189.72
52-Week Range$150.38 - $191.10
Volume3.58 million shs
Average Volume2.68 million shs
Market Capitalization$137.40 billion
P/E Ratio17.10
Dividend Yield2.79%
Beta1.36

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:AMGN
CUSIP03116210
Phone+1-805-4471000

Debt

Debt-to-Equity Ratio1.05%
Current Ratio6.07%
Quick Ratio5.72%

Price-To-Earnings

Trailing P/E Ratio17.0984643179765
Forward P/E Ratio14.92
P/E Growth2.77

Sales & Book Value

Annual Sales$22.99 billion
Price / Sales5.98
Cash Flow$14.64 per share
Price / Cash12.93
Book Value$40.16 per share
Price / Book4.71

Profitability

Trailing EPS$11.07
Net Income$7.72 billion
Net Margins35.54%
Return on Equity29.90%
Return on Assets11.80%

Miscellaneous

Employees19,200
Outstanding Shares725,910,000

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share on Thursday, March 8th. This represents a $5.28 annualized dividend and a yield of 2.79%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $1.15. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its Board of Directors has initiated a share buyback program on Thursday, October 26th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) released its quarterly earnings data on Wednesday, October, 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.11 by $0.16. The medical research company earned $5.77 billion during the quarter, compared to analysts' expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm's revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.02 earnings per share. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY17 earnings guidance on Wednesday, October, 25th. The company provided earnings per share guidance of $12.50-12.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.56. The company issued revenue guidance of $22.7-23 billion, compared to the consensus revenue estimate of $22.86 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2018?

20 Wall Street analysts have issued 1-year price targets for Amgen's stock. Their forecasts range from $161.00 to $210.00. On average, they anticipate Amgen's stock price to reach $190.56 in the next twelve months. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
  • 2. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
  • 3. According to Zacks Investment Research, "Amgen beat expectations for both earnings and sales in Q3 and raised its earnings guidance for 2017. However sales declined year over year. Meanwhile sales of key drug Repatha disappointed in the quarter. Amgen’s newer drugs – Prolia, Xgeva, Vectibix and Sensipar – are performing well. Amgen is also progressing with its pipeline including biosimilar drugs. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature drugs. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta and Epogen could start facing the same next year. Also the softness in Enbrel sales due to stiff competitive pressure is a key cause for concern. Meanwhile, uptake of Repatha has been slow." (10/30/2017)
  • 4. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)

Are investors shorting Amgen?

Amgen saw a increase in short interest in December. As of December 15th, there was short interest totalling 10,311,958 shares, an increase of 23.2% from the November 30th total of 8,373,413 shares. Based on an average daily volume of 3,283,091 shares, the short-interest ratio is presently 3.1 days. Currently, 1.4% of the shares of the stock are sold short.

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • David W. Meline, Executive Vice President, Chief Financial Officer (Age 60)
  • Sean E. Harper, Executive Vice President - Research and Development (Age 54)
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations (Age 62)
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives (Age 60)
  • Esteban Santos, Executive Vice President, Operations (Age 49)
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer (Age 55)
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary (Age 56)
  • Lori A. Johnston, Senior Vice President (Age 52)
  • David A. Piacquad, Senior Vice President - Business Development (Age 60)

Who owns Amgen stock?

Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.46%), National Pension Service (0.08%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.04%), Bartlett & Co. LLC (0.04%) and Intermede Investment Partners Ltd (0.03%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Wasatch Advisors Inc., Stralem & Co. Inc., American Financial Network Advisory Services LLC, World Asset Management Inc, Chelsea Counsel Co. and DAVENPORT & Co LLC. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Cardinal Capital Management Inc., Stillwater Investment Management LLC, Personal Capital Advisors Corp, National Pension Service and Broadleaf Partners LLC. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $189.28.

How big of a company is Amgen?

Amgen has a market capitalization of $137.40 billion and generates $22.99 billion in revenue each year. The medical research company earns $7.72 billion in net income (profit) each year or $11.07 on an earnings per share basis. Amgen employs 19,200 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is 1 Amgen Center Dr, THOUSAND OAKS, CA 91320-1730, United States. The medical research company can be reached via phone at +1-805-4471000 or via email at [email protected]


MarketBeat Community Rating for Amgen (AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,021 (Vote Outperform)
Underperform Votes:  631 (Vote Underperform)
Total Votes:  1,652
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.452.452.552.52
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $190.56$190.56$191.06$185.68
Price Target Upside: 5.95% upside7.85% upside4.42% upside3.04% upside

Amgen (NASDAQ:AMGN) Consensus Price Target History

Price Target History for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018OppenheimerSet Price TargetBuy$205.00LowView Rating Details
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
12/28/2017MizuhoSet Price TargetBuy$192.00LowView Rating Details
12/18/2017CitigroupDowngradeNeutralLowView Rating Details
12/15/2017Goldman Sachs GroupDowngradeConviction-Buy -> BuyHighView Rating Details
11/30/2017CannReiterated RatingBuy$205.00HighView Rating Details
11/1/2017ArgusDowngradeBuy -> Hold$175.22 -> $195.00N/AView Rating Details
10/26/2017BMO Capital MarketsReiterated RatingMarket Perform$198.00N/AView Rating Details
10/26/2017Morgan StanleyLower Price TargetOverweight$196.00 -> $193.00N/AView Rating Details
10/26/2017Royal Bank of CanadaLower Price TargetSector Perform$192.00 -> $188.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$180.00 -> $190.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/AView Rating Details
9/29/2017Credit Suisse GroupReiterated RatingNeutral$177.00 -> $186.00MediumView Rating Details
9/25/2017Jefferies GroupReiterated RatingBuy$200.00LowView Rating Details
7/26/2017Deutsche BankReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/22/2017CowenReiterated RatingOutperform$209.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CoReiterated RatingHoldN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Amgen (NASDAQ:AMGN) Earnings History and Estimates Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$3.02N/AView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.75 billion$5.77 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
4/24/2012Q1 2012$1.43$1.59ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
10/25/2010Q3 2010$1.26$1.36ViewN/AView Earnings Details
7/29/2010Q2 2010$1.28$1.34ViewN/AView Earnings Details
4/21/2010Q1 2010$1.23$1.28ViewN/AView Earnings Details
1/25/2010Q4 2009$1.11$1.05ViewN/AView Earnings Details
10/21/2009Q3 2009$1.25$1.49ViewN/AView Earnings Details
7/27/2009Q2 2009$1.15$1.27ViewN/AView Earnings Details
4/23/2009Q1 2009$1.13$1.08ViewN/AView Earnings Details
1/26/2009Q4 2008$1.04$1.04ViewN/AView Earnings Details
10/22/2008Q3 2008$1.06$1.21ViewN/AView Earnings Details
7/28/2008Q2 2008$0.98$1.13ViewN/AView Earnings Details
4/24/2008Q1 2008$1.02$1.10ViewN/AView Earnings Details
1/24/2008Q4 2007$0.92$0.97ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amgen (NASDAQ:AMGN) Earnings Estimates

2018 EPS Consensus Estimate: $12.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$3.04$3.30$3.20
Q2 20183$3.08$3.43$3.25
Q3 20183$3.16$3.32$3.22
Q4 20183$3.03$3.17$3.11
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Next Dividend:3/8/2018
Annual Dividend:$4.60
Dividend Yield:2.43%
Dividend Growth:23.50% (3 Year Average)
Payout Ratio:41.55% (Trailing 12 Months of Earnings)
36.25% (Based on This Year's Estimates)
36.33% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/12/2017quarterly$1.322.98%2/14/20182/15/20183/8/2018
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.48%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Sean E. HarperEVPSell1,525$185.62$283,070.50View SEC Filing  
12/12/2017Sean E HarperEVPSell1,525$176.83$269,665.7556,106View SEC Filing  
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.5057,631View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.8024,214View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.0023,097View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.5232,350View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.2542,248View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.0015,150View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.303,582View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.9018,589View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.2541,041View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.0018,343View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.1226,879View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
What to Expect From Amgen, Inc. in 2018What to Expect From Amgen, Inc. in 2018
www.fool.com - January 21 at 8:58 AM
Amgen’s Aimovig is Expected to Witness Steady Growth in 2018Amgen’s Aimovig is Expected to Witness Steady Growth in 2018
finance.yahoo.com - January 19 at 8:50 AM
Leerink Swann Analysts Decrease Earnings Estimates for Amgen, Inc. (AMGN)Leerink Swann Analysts Decrease Earnings Estimates for Amgen, Inc. (AMGN)
www.americanbankingnews.com - January 19 at 8:42 AM
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical OncologyOverall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
finance.yahoo.com - January 18 at 3:23 PM
How Amgen’s Enbrel and Nplate Are Positioned for 2018How Amgen’s Enbrel and Nplate Are Positioned for 2018
finance.yahoo.com - January 18 at 7:52 AM
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) LabelFDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
finance.yahoo.com - January 18 at 7:52 AM
Amgen, Inc. (AMGN) EVP Sean E. Harper Sells 1,525 SharesAmgen, Inc. (AMGN) EVP Sean E. Harper Sells 1,525 Shares
www.americanbankingnews.com - January 17 at 9:32 PM
How a Juno Takeover Could Boost CelgeneHow a Juno Takeover Could Boost Celgene
finance.yahoo.com - January 17 at 3:22 PM
Does Amgen Inc’s (NASDAQ:AMGN) Debt Level Pose A Problem?Does Amgen Inc’s (NASDAQ:AMGN) Debt Level Pose A Problem?
finance.yahoo.com - January 17 at 11:37 AM
Will 2018 Be Amgen Inc.'s Best Year Yet?Will 2018 Be Amgen Inc.'s Best Year Yet?
finance.yahoo.com - January 17 at 11:37 AM
 Brokerages Anticipate Amgen, Inc. (AMGN) Will Post Quarterly Sales of $5.84 Billion Brokerages Anticipate Amgen, Inc. (AMGN) Will Post Quarterly Sales of $5.84 Billion
www.americanbankingnews.com - January 16 at 10:52 PM
Will Amgen (AMGN) Continue to Tread Growth Path This Year? - NasdaqWill Amgen (AMGN) Continue to Tread Growth Path This Year? - Nasdaq
www.nasdaq.com - January 16 at 3:21 PM
Zacks: Analysts Anticipate Amgen, Inc. (AMGN) to Announce $3.04 EPSZacks: Analysts Anticipate Amgen, Inc. (AMGN) to Announce $3.04 EPS
www.americanbankingnews.com - January 14 at 3:30 AM
Amgen, Inc. (AMGN) Receives Average Rating of "Hold" from AnalystsAmgen, Inc. (AMGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 13 at 1:58 AM
June 2019 Options Now Available For Amgen (AMGN)June 2019 Options Now Available For Amgen (AMGN)
www.nasdaq.com - January 10 at 3:23 PM
See what the IHS Markit Score report has to say about Amgen Inc.See what the IHS Markit Score report has to say about Amgen Inc.
finance.yahoo.com - January 10 at 3:23 PM
How Incyte’s Jakafi Performed in 3Q17How Incyte’s Jakafi Performed in 3Q17
finance.yahoo.com - January 10 at 7:44 AM
5 Things Amgen's CEO Just Said That Investors Need to Know5 Things Amgen's CEO Just Said That Investors Need to Know
finance.yahoo.com - January 10 at 7:44 AM
Amgen Announces Acceptance of MAA for Evenity in EuropeAmgen Announces Acceptance of MAA for Evenity in Europe
finance.yahoo.com - January 9 at 3:21 PM
Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology CompoundBiocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound
finance.yahoo.com - January 9 at 7:57 AM
European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
finance.yahoo.com - January 8 at 11:09 AM
2 Top Dividend Stocks to Buy in 2018 2 Top Dividend Stocks to Buy in 2018
www.fool.com - January 7 at 7:23 AM
BofA: The Biotech Sector Is In A Perfect Storm For M&A - BenzingaBofA: The Biotech Sector Is In A 'Perfect Storm' For M&A - Benzinga
www.benzinga.com - January 6 at 7:49 AM
FDA OKs expanded use for Amgens Xgeva - Seeking AlphaFDA OKs expanded use for Amgen's Xgeva - Seeking Alpha
seekingalpha.com - January 6 at 7:49 AM
BofA: The Biotech Sector Is In A Perfect Storm For M&ABofA: The Biotech Sector Is In A 'Perfect Storm' For M&A
finance.yahoo.com - January 6 at 7:49 AM
FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple MyelomaFDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
finance.yahoo.com - January 5 at 3:23 PM
FDA expands use of Amgens blockbuster drugFDA expands use of Amgen's blockbuster drug
finance.yahoo.com - January 5 at 3:23 PM
Amgen (AMGN) Given a $205.00 Price Target by Oppenheimer AnalystsAmgen (AMGN) Given a $205.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - January 5 at 12:02 PM
Amgen To Present At The 36th Annual J.P. Morgan Healthcare ConferenceAmgen To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 7:26 AM
XLV, AMGN, GILD, LLY: Large Outflows Detected at ETFXLV, AMGN, GILD, LLY: Large Outflows Detected at ETF
www.nasdaq.com - January 4 at 3:22 PM
Arrowhead rides Amgen rally, shares up 26% - Seeking AlphaArrowhead rides Amgen rally, shares up 26% - Seeking Alpha
seekingalpha.com - January 4 at 7:28 AM
Why Amgens Stock May Rise Over 30%: Todd GordonWhy Amgen's Stock May Rise Over 30%: Todd Gordon
finance.yahoo.com - January 4 at 7:27 AM
Amgen (AMGN) Downgraded by VetrAmgen (AMGN) Downgraded by Vetr
www.americanbankingnews.com - January 4 at 12:14 AM
One big biotech stock looks poised for a breakout in 2018, technician saysOne big biotech stock looks poised for a breakout in 2018, technician says
finance.yahoo.com - January 2 at 3:25 PM
Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : January 1, 2018Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : January 1, 2018
finance.yahoo.com - January 1 at 3:21 PM
5 Surprising Buys For A Safe 55.8% Dividend Yield5 Surprising Buys For A Safe 55.8% Dividend Yield
finance.yahoo.com - December 31 at 3:23 PM
Zacks: Analysts Expect Amgen, Inc. (AMGN) Will Post Quarterly Sales of $5.84 BillionZacks: Analysts Expect Amgen, Inc. (AMGN) Will Post Quarterly Sales of $5.84 Billion
www.americanbankingnews.com - December 30 at 9:40 AM
Amgen (AMGN) Given a $192.00 Price Target at MizuhoAmgen (AMGN) Given a $192.00 Price Target at Mizuho
www.americanbankingnews.com - December 29 at 3:34 PM
How To Maximize Dividend Yield In Your Portfolio (VIG)How To Maximize Dividend Yield In Your Portfolio (VIG)
finance.yahoo.com - December 29 at 9:25 AM
Amgen, Inc. (AMGN) Short Interest Up 23.2% in DecemberAmgen, Inc. (AMGN) Short Interest Up 23.2% in December
www.americanbankingnews.com - December 29 at 3:04 AM
$3.04 Earnings Per Share Expected for Amgen, Inc. (AMGN) This Quarter$3.04 Earnings Per Share Expected for Amgen, Inc. (AMGN) This Quarter
www.americanbankingnews.com - December 28 at 8:18 AM
Oppenheimer Analysts Give Amgen (AMGN) a $205.00 Price TargetOppenheimer Analysts Give Amgen (AMGN) a $205.00 Price Target
www.americanbankingnews.com - December 24 at 11:50 PM
Amgen estimates $6B-plus US tax bill as it repatriates cash - Seeking AlphaAmgen estimates $6B-plus US tax bill as it repatriates cash - Seeking Alpha
seekingalpha.com - December 23 at 8:45 PM
Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash - ReutersAmgen estimates its U.S. tax bill at over $6 billion as it repatriates cash - Reuters
www.reuters.com - December 23 at 1:42 AM
Amgen (AMGN) Announces Expected Impact of U.S. Tax Reform LegislationAmgen (AMGN) Announces Expected Impact of U.S. Tax Reform Legislation
www.streetinsider.com - December 22 at 8:39 PM
Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cashAmgen estimates its U.S. tax bill at over $6 billion as it repatriates cash
finance.yahoo.com - December 22 at 8:39 PM
Amgen sees $6-$6.5 billion in tax expenses from new lawAmgen sees $6-$6.5 billion in tax expenses from new law
finance.yahoo.com - December 22 at 8:39 PM
Amgen estimates $6B-plus U.S. tax bill as it repatriates cashAmgen estimates $6B-plus U.S. tax bill as it repatriates cash
seekingalpha.com - December 22 at 8:36 PM
Amgen (AMGN) PT Set at $192.00 by MizuhoAmgen (AMGN) PT Set at $192.00 by Mizuho
www.americanbankingnews.com - December 22 at 3:58 PM
Q2 2018 EPS Estimates for Amgen, Inc. Increased by Analyst (AMGN)Q2 2018 EPS Estimates for Amgen, Inc. Increased by Analyst (AMGN)
www.americanbankingnews.com - December 22 at 1:58 PM

SEC Filings

Amgen (NASDAQ:AMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amgen (NASDAQ AMGN) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.